CAPS
MCID: CTS005
MIFTS: 44

Catastrophic Antiphospholipid Syndrome (CAPS)

Categories: Blood diseases, Bone diseases, Immune diseases, Rare diseases

Aliases & Classifications for Catastrophic Antiphospholipid Syndrome

MalaCards integrated aliases for Catastrophic Antiphospholipid Syndrome:

Name: Catastrophic Antiphospholipid Syndrome 53 59 72
Catastrophic Antiphospholipid Antibody Syndrome 53
Cryopyrin-Associated Periodic Syndromes 72
Thrombotic Storm 53
Catastrophic Aps 59
Caps 59

Classifications:



External Ids:

ICD10 via Orphanet 34 D68.6
Orphanet 59 ORPHA464343
UMLS 72 C2316212 C3662487

Summaries for Catastrophic Antiphospholipid Syndrome

NIH Rare Diseases : 53 Catastrophic antiphospholipid syndrome (CAPS) is a rare form of antiphospholipid syndrome (APS). In CAPS multiple blood clots form throughout the body over a short period of time (usually within a week). CAPS is a medical emergency, as clots can cause life-threatening multi-organ failure. The cause of CAPS is unknown. A widely accepted explanation is that it is caused by a combination of gene mutations (making one more susceptible to CAPS) and an environmental trigger, such as an infection, trauma, or surgery.

MalaCards based summary : Catastrophic Antiphospholipid Syndrome, also known as catastrophic antiphospholipid antibody syndrome, is related to antiphospholipid syndrome and thrombocytopenia. An important gene associated with Catastrophic Antiphospholipid Syndrome is APOH (Apolipoprotein H), and among its related pathways/superpathways are Response to elevated platelet cytosolic Ca2+ and Formation of Fibrin Clot (Clotting Cascade). The drugs Metformin and Trandolapril have been mentioned in the context of this disorder. Affiliated tissues include brain, testes and heart, and related phenotypes are homeostasis/metabolism and hematopoietic system

Wikipedia : 75 Catastrophic antiphospholipid syndrome (CAPS), also known as Asherson's syndrome, is an acute and... more...

Related Diseases for Catastrophic Antiphospholipid Syndrome

Diseases related to Catastrophic Antiphospholipid Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 261)
# Related Disease Score Top Affiliating Genes
1 antiphospholipid syndrome 31.7 MTHFR F5 F3 CD40LG APOH ADAMTS13
2 thrombocytopenia 31.2 F3 APOH ADAMTS13
3 heparin-induced thrombocytopenia 31.1 F3 CD40LG
4 hemolytic-uremic syndrome 30.7 F3 CFH ADAMTS13
5 thrombotic thrombocytopenic purpura 30.5 F3 CFH APOH ADAMTS13
6 connective tissue disease 30.5 CD40LG APOH ADAMTS13
7 acute kidney failure 30.5 CFH ADAMTS13
8 syphilis 30.5 CD40LG APOH
9 acquired hemophilia 30.4 F5 F3
10 mixed connective tissue disease 30.4 APOH ADAMTS13
11 purpura 30.2 PROC F3 APOH ADAMTS13
12 hepatic infarction 30.2 MTHFR F3 APOH
13 purpura fulminans 30.2 PROC F3
14 central retinal vein occlusion 30.0 MTHFR F5 APOH
15 branch retinal artery occlusion 29.9 MTHFR F3 APOH
16 coronary thrombosis 29.9 SERPINE1 F3
17 patent foramen ovale 29.8 MTHFR F5 APOH
18 disseminated intravascular coagulation 29.8 SERPINE1 F5 F3 ADAMTS13
19 protein c deficiency 29.5 PROC MTHFR F5
20 ischemic colitis 29.5 SERPINE1 F5 APOH
21 intracranial thrombosis 29.4 MTHFR F5 F3 APOH
22 protein s deficiency 29.4 MTHFR F5 F3 APOH
23 placenta disease 29.4 MTHFR F5 F3 APOH
24 budd-chiari syndrome 29.4 MTHFR F5 F3 APOH
25 cerebrovascular disease 29.0 SERPINE1 MTHFR F5
26 retinal vein occlusion 28.9 SERPINE1 MTHFR F5 APOH
27 pulmonary embolism 28.8 SERPINE1 MTHFR F5 F3 APOH
28 pre-eclampsia 28.8 SERPINE1 MTHFR F5 F3 APOH
29 thrombophlebitis 28.8 SERPINE1 MTHFR F5 APOH
30 retinal artery occlusion 28.8 SERPINE1 MTHFR F5 APOH
31 thrombophilia due to thrombin defect 28.3 SERPINE1 PROC MTHFR F5 F3 APOH
32 vascular disease 28.2 SERPINE1 MTHFR F5 F3 APOH
33 hellp syndrome 28.1 SERPINE1 MTHFR F5 F3 CFH APOH
34 stroke, ischemic 28.1 SERPINE1 MTHFR F5 F3 APOH ADAMTS13
35 thrombophilia 27.8 SERPINE1 PROC MTHFR F5 F3 APOH
36 myocardial infarction 27.7 SERPINE1 MTHFR F5 F3 CD40LG ADAMTS13
37 thrombosis 27.2 SERPINE1 PROC MTHFR F5 F3 APOH
38 thrombotic microangiopathy 10.6
39 erythema infectiosum 10.5 CD40LG APOH
40 thrombotic thrombocytopenic purpura, congenital 10.5 CFH ADAMTS13
41 systemic lupus erythematosus 10.5
42 may-thurner syndrome 10.5 F5 APOH
43 acanthamoeba keratitis 10.5 F5 APOH
44 lupus erythematosus 10.5
45 fournier gangrene 10.5 F3 CD40LG
46 hemolytic anemia 10.5
47 pregnancy loss, recurrent 1 10.5 F5 APOH
48 primary thrombocytopenia 10.5 CD40LG ADAMTS13
49 prothrombin deficiency, congenital 10.4 F5 APOH
50 autoimmune disease 10.4

Graphical network of the top 20 diseases related to Catastrophic Antiphospholipid Syndrome:



Diseases related to Catastrophic Antiphospholipid Syndrome

Symptoms & Phenotypes for Catastrophic Antiphospholipid Syndrome

MGI Mouse Phenotypes related to Catastrophic Antiphospholipid Syndrome:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 9.81 ADAMTS13 APOH CD40LG CFH F3 F5
2 hematopoietic system MP:0005397 9.8 ADAMTS13 CD40LG CFH CRLS1 F3 PROC
3 immune system MP:0005387 9.5 ADAMTS13 CD40LG CFH CRLS1 F3 PROC
4 mortality/aging MP:0010768 9.28 ADAMTS13 APOH CD40LG CFH F3 F5

Drugs & Therapeutics for Catastrophic Antiphospholipid Syndrome

Drugs for Catastrophic Antiphospholipid Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 480)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Metformin Approved Phase 4 657-24-9 4091 14219
2
Trandolapril Approved Phase 4 87679-37-6 5484727
3
Captopril Approved Phase 4 62571-86-2 44093
4
Tramadol Approved, Investigational Phase 4 27203-92-5 33741
5
Didanosine Approved Phase 4 69655-05-6 50599
6
Lamivudine Approved, Investigational Phase 4 134678-17-4 60825
7
Efavirenz Approved, Investigational Phase 4 154598-52-4 64139
8
Histamine Approved, Investigational Phase 4 51-45-6 774
9
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
10
Citalopram Approved Phase 4 59729-33-8 2771
11
Sertraline Approved Phase 4 79617-96-2 68617
12
Doxycycline Approved, Investigational, Vet_approved Phase 4 564-25-0 54671203
13
Topiramate Approved Phase 4 97240-79-4 5284627
14
Tacrolimus Approved, Investigational Phase 4 104987-11-3 445643 439492 6473866
15
Mirtazapine Approved Phase 4 61337-67-5, 85650-52-8 4205
16
Risperidone Approved, Investigational Phase 4 106266-06-2 5073
17
Cocaine Approved, Illicit Phase 4 50-36-2 446220 5760
18
Ziprasidone Approved Phase 4 146939-27-7 60854
19
Lamotrigine Approved, Investigational Phase 4 84057-84-1 3878
20
Carbamazepine Approved, Investigational Phase 4 298-46-4 2554
21
Levetiracetam Approved, Investigational Phase 4 102767-28-2 441341
22
Simvastatin Approved Phase 4 79902-63-9 54454
23
Nicotinamide Approved, Investigational Phase 4 98-92-0 936
24
Memantine Approved, Investigational Phase 4 19982-08-2 4054
25
Propofol Approved, Investigational, Vet_approved Phase 4 2078-54-8 4943
26
Iron Approved, Experimental Phase 4 15438-31-0, 7439-89-6 23925 27284
27
tannic acid Approved Phase 4 1401-55-4
28
Benzocaine Approved, Investigational Phase 4 94-09-7, 1994-09-7 2337
29
Heparin Approved, Investigational Phase 4 9005-49-6 46507594 772
30
Povidone Approved Phase 4 9003-39-8
31
Povidone-iodine Approved Phase 4 25655-41-8
32
Iodine Approved, Investigational Phase 4 7553-56-2 807
33
Ferrous fumarate Approved Phase 4 141-01-5
34 Taurolidine Approved, Investigational Phase 4 19388-87-5
35
Sodium citrate Approved, Investigational Phase 4 68-04-2
36
Dexmedetomidine Approved, Vet_approved Phase 4 113775-47-6 68602 5311068
37
Colestipol Approved Phase 4 26658-42-4
38
Prazosin Approved Phase 4 19216-56-9 4893
39
Promethazine Approved, Investigational Phase 4 60-87-7 4927
40
Suvorexant Approved, Investigational Phase 4 1030377-33-3
41
Diphenhydramine Approved, Investigational Phase 4 58-73-1, 147-24-0 3100
42
Lopinavir Approved Phase 4 192725-17-0 92727
43
Paroxetine Approved, Investigational Phase 4 61869-08-7 43815
44
Propranolol Approved, Investigational Phase 4 525-66-6 4946
45
Ritonavir Approved, Investigational Phase 4 155213-67-5 392622
46
Ambrisentan Approved, Investigational Phase 4 177036-94-1 6918493
47
Spironolactone Approved Phase 4 1952-01-7, 52-01-7 5833
48
mometasone furoate Approved, Investigational, Vet_approved Phase 4 83919-23-7
49
Ginseng Approved, Investigational, Nutraceutical Phase 4 50647-08-0
50
Folic acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037

Interventional clinical trials:

(show top 50) (show all 415)
# Name Status NCT ID Phase Drugs
1 A Randomized , Controlled, Doulbe Blind Placebo Trial To Evaluate The Efficacy and the Tolerance of an Omega 3 Fatty Acids Supplementation in ADHD Children Unknown status NCT00770627 Phase 4
2 Colecalciferol as an Add-on Treatment to Subcutaneously Administered Interferon-beta-1b for Treatment of MS Unknown status NCT01339676 Phase 4 Colecalciferol;Placebo capsules
3 Acute Haemodynamic Effects of Treatment With ACE-Inhibitors in Patients With Symptomatic Aortic Stenosis (ACCESS) Unknown status NCT00252317 Phase 4 Captopril and Trandolapril;Captopril Test Dose and Trandolapril
4 Evaluate the Efficacy of Xuebijing Injection in Acute Exacerbations of COPD:a Multicentre Randomised Controlled Trial Unknown status NCT02937974 Phase 4 Xuebijing;Placebo
5 Placebo Controlled Study Using Lovaza as Treatment for Non-Alcoholic Fatty Liver Disease Unknown status NCT00941642 Phase 4 Lovaza;placebo control
6 A Double-Blind, Placebo-Controlled, Flexible-Dose Pilot Clinical Trial of Once-Daily Extended-Release Tramadol for the Treatment of PTSD Unknown status NCT01517711 Phase 4 Tramadol;Placebo
7 Treatment of Plantar Fasciitis With Injection af Platelet-rich Plasma Into the Origin of the Plantar Fascia - a Prospective, Randomized and Double Blinded Study. Unknown status NCT01509274 Phase 4
8 Dose Related Decrease in Triglycerides in Patients With Hypertriglyceridemia and Treated With Lovaza. Unknown status NCT00934219 Phase 4 Omega-3-Acid Ethyl Esters
9 A Randomised, Multi-Centre, Open-Label Study in Well-Controlled Treatment-Experienced HIV-Infected Patients to Assess Compliance With a Once-Daily Regimen of Lamivudine, Efavirenz and Didanosine Versus Continuation of Current Anti-Retroviral Regimen Delivered at Least Twice Daily Unknown status NCT00214435 Phase 4 once daily minimum 3-drug regimen of anti-retroviral medications
10 Efficacy and Safety of Danggui-Sayuk-Ga-Osuyu-Saenggang-tang on Korean Patients With Cold Hypersensitivity in the Hands Completed NCT02645916 Phase 4 Danggui-Sayuk-Ga-Osuyu-Saenggang-tang;Placebo: corn starch
11 Effect of Korean Red Ginseng on Women With Cold Hypersensitivity of Hands and Feet : a Randomized, Double-blind, Placebo-controlled Trial Completed NCT01664156 Phase 4 Korean red ginseng;Placebo
12 A Trial to Determine the Long-term Durability of Virologic Suppression in Kaletra Recipients With Imperfect Adherence Completed NCT00785616 Phase 4
13 Cathflo Activase (Alteplase) Pediatric Study (CAPS) Completed NCT00307580 Phase 4 Cathflo Activase (Alteplase)
14 Serum Levels of Doxycycline at the Time of Abortion With Two Dosing Regimens Completed NCT00177333 Phase 4 Doxycycline
15 A Placebo-controlled Trial of Adjunctive Quetiapine for Refractory PTSD Completed NCT00292370 Phase 4 Open Label (OL) Paroxetine;Placebo;Quetiapine
16 Topiramate in the Treatment of Post Traumatic Stress Disorder (PTSD) Completed NCT00203463 Phase 4 topiramate
17 Pregnenolone Augmentation in the Treatment of Patients With Recent-Onset Schizophrenia: an 8-week, Randomized, Double-blind, Placebo-controlled Trial Completed NCT00847600 Phase 4
18 Randomized Clinical Trial to Study the Topiramate Efficacy for Posttraumatic Disorder Treatment Completed NCT00725920 Phase 4 Topiramate;placebo control group
19 An Open-Label Trial of Memantine for Cognitive Impairment in Patients With Post-Traumatic Stress Disorder Completed NCT02258828 Phase 4 Memantine
20 Prazosin Treatment for Combat Trauma PTSD Nightmares and Sleep Disturbance Completed NCT00108420 Phase 4 Prazosin
21 Paroxetine Treatment in Outpatients With Comorbid PTSD and Substance Dependence Completed NCT00330239 Phase 4 Paroxetine CR
22 Immediate and Delayed Loading of 4.1 mm and 4.8 mm Implants in the Posterior Mandible & Maxilla: A Controlled Randomized Study of Single or 2-4 Unit Restorations Loaded Immediately After Surgery or Four Weeks After Surgery Completed NCT00782171 Phase 4
23 Risperidone Monotherapy in the Treatment of PTSD in Women Survivors of Domestic Abuse and Rape Trauma: a Double-Blind, Placebo Controlled, Randomized Clinical Trial Completed NCT00208182 Phase 4 Risperidone
24 Exercise and Phytoestrogens: a Synergistic Effect on Factors Predisposing to CVD in Postmenopausal Women Completed NCT01048606 Phase 4
25 Locking of Totally Implanted Venous Access Devices and Tunneled Catheters With or Without Heparin: a Randomised Open-labeled Controlled Trial Completed NCT00994136 Phase 4 normal saline
26 Randomized, Controlled, Double Blind Trial to Evaluate Sedation and Quality of Life in High-risk, Critically Ill Patients Treated With Oral Melatonin Completed NCT00470821 Phase 4 Oral melatonin 3mg BID;Placebo
27 Geodon (Ziprasidone) for Posttraumatic Stress Disorder Completed NCT00208208 Phase 4 Ziprasidone
28 A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Determine the Efficacy and Safety of Topiramate in the Treatment of Posttraumatic Stress Disorder in Civilians Completed NCT00208130 Phase 4 Topiramate
29 Neural Circuits in Women With Abuse and Posttraumatic Stress Disorder Completed NCT01681849 Phase 4 Placebo;Paroxetine
30 A Placebo-Controlled Study of Mirtazapine for PTSD in OIF/OEF Veterans Completed NCT00302107 Phase 4 Mirtazapine;Placebo
31 Combined Mirtazapine and Selective Serotonin Reuptake Inhibitor (SSRI) Treatment of Post-traumatic Stress Disorder (PTSD) Completed NCT01178671 Phase 4 Mirtazapine;Sertraline
32 Atomoxetine in Comorbid ADHD/PTSD: A Pilot, Placebo-Controlled Feasibility Study Completed NCT02287038 Phase 4 Atomoxetine 80 MG
33 Evaluation of Clinical and Safety Outcomes Associated With Conversion From Brand-Name to Generic Tacrolimus Products in High Risk Transplant Recipients Completed NCT02014103 Phase 4 Tacrolimus
34 Efficacy and Safety of Furocyst in Patients With Poly Cystic Ovary Syndrome Completed NCT02789488 Phase 4
35 A Multicentre, Double-blind, Randomized, Phase IV Clinical Trial Comparing the Safety, Tolerability and Efficacy of Levetiracetam Versus Lamotrigine and Carbamazepine in the Oral Antiepileptic Therapy of Newly Diagnosed Elderly Patients With Focal Epilepsy. Completed NCT00438451 Phase 4 Levetiracetam;Carbamazepine;Lamotrigine
36 A 12-week, Randomized, Double-blind, Parallel-group, Placebo-controlled Trial of Citicoline as an add-on Therapy Will be Conducted in 200 Outpatients With Bipolar I Disorder and Cocaine Dependence. Completed NCT00619723 Phase 4 Citicoline;Placebo
37 Energy Expenditure Assessment of Preterm Infant With Very Low Birth Weight Fed With Human Milk or Preterm Formula Completed NCT00769509 Phase 4
38 Antidepressant Treatment at an Inner City Asthma Clinic Completed NCT01324700 Phase 4 High severity group: Escitalopram;High severity group: Placebo;Low severity group: Escitalopram;Low severity group: Placebo
39 Magnetic Resonance Characterization of Carotid Atherosclerotic Plaque in Vivo: Effect of High Density Lipoprotein Elevation on Plaque Morphology Completed NCT00307307 Phase 4 Niacin/simvastatin compared to simvastatin alone at 2 doses
40 Randomized Double-blind Placebo-controlled Trial of Memantine Hydrochloride for the Treatment of Childhood-onset Epileptic Encephalopathies Recruiting NCT03779672 Phase 4 Memantine Hydrochloride 10 mg
41 Skin Antisepsis With Chlorhexidine-Alcohol Versus Povidone Iodine-Alcohol, Combined or Not With Use of a Bundle of New Devices, for Prevention of Intravascular-catheter Colonization and Catheter Failure: An Open Label, Single Center, Randomized Controlled, Two-by-two Factorial Trial Recruiting NCT03757143 Phase 4 Povidone-Iodine-Alcohol;Chlorhexidine-Alcohol
42 Amino Acid Chelated Iron Versus Ferrous Fumarate in the Treatment of Iron Deficiency Anemia With Pregnancy: Randomized Controlled Trial Recruiting NCT03830034 Phase 4 Amino Acid chelated iron tab 15 mg;Ferrous Fumarate tab 350 mg( 115 mg elemental iron)
43 Taurolidine Citrate and Unfractionated Heparin Combination Versus Unfractionated Heparin Alone in Prevention of Inflammation in Hemodialysis Catheters. Recruiting NCT03539718 Phase 4 Taurolidine heparin;Heparin Sodium
44 Effect Of Dexmedetomidine Infusion On Sublingual Microcirculation In Patients Undergoing On Pump Coronary Artery Bypass Graft Surgery Recruiting NCT02714725 Phase 4 Dexmedetomidine;Placebo for Dexmedetomidine normal saline infusion;Propofol infusion
45 Treatment Effect of Colesevelam for Bile Acid Diarrhoea - a Randomised Placebo-controlled Trial Recruiting NCT03876717 Phase 4 Colesevelam Hydrochloride;Placebo oral capsule
46 Propranolol Reactivation Mismatch (PRM) Treatment for PTSD: A Pilot Study Not yet recruiting NCT03652922 Phase 4 Reactivation Mismatch
47 Administration of Prazosin to Prevent PTSD After Sexual Assault Not yet recruiting NCT03997864 Phase 4 Prazosin;Placebos
48 Suvorexant: A Dual Orexin Receptor Antagonist for Treating Sleep Disturbance inPosttraumatic Stress Not yet recruiting NCT03642028 Phase 4 Suvorexant
49 PTSD Symptom Reduction by Propranolol Given After Memory Activation Terminated NCT00645450 Phase 4 Propranolol;Placebo
50 A Phase IV Open Label Investigation of the Efficacy and Durability of Once Daily Antiretroviral Therapy With Kaletra and Viread in Antiretroviral Naïve Patients. Terminated NCT00679926 Phase 4 Lopinavir/ritonavir and tenofovir

Search NIH Clinical Center for Catastrophic Antiphospholipid Syndrome

Inferred drug relations via UMLS 72 / NDF-RT 51 :


anakinra

Genetic Tests for Catastrophic Antiphospholipid Syndrome

Anatomical Context for Catastrophic Antiphospholipid Syndrome

MalaCards organs/tissues related to Catastrophic Antiphospholipid Syndrome:

41
Brain, Testes, Heart, Breast, Liver, Bone, Lung

Publications for Catastrophic Antiphospholipid Syndrome

Articles related to Catastrophic Antiphospholipid Syndrome:

(show top 50) (show all 454)
# Title Authors PMID Year
1
Eculizumab in refractory catastrophic antiphospholipid syndrome: a case report and systematic review of the literature. 38
31214910 2019
2
Mortality in patients with systemic lupus erythematosus in Colombia: a case series. 38
30989407 2019
3
Catastrophic antiphospholipid syndrome as a complication of systemic sclerosis. 38
31309781 2019
4
Simultaneous Left and Right Ventricular Thrombi Caused by Catastrophic Antiphospholipid Syndrome (CAPS). 38
31356115 2019
5
Revisiting the role of therapeutic plasma exchange in the management of catastrophic antiphospholipid syndrome. 38
30720923 2019
6
CAPS criteria fail to identify most severely-ill thrombotic antiphospholipid syndrome patients requiring intensive care unit admission. 38
31253464 2019
7
Catastrophic antiphospholipid syndrome and pregnancy. Clinical report. 38
29284338 2019
8
Catastrophic Antiphospholid Syndrome - An Unusual Case Report. 38
31435147 2019
9
A case-report of successful use of thromboelastography to manage anticoagulation therapy in a patient with concomitant catastrophic antiphospholipid syndrome and heparin-induced thrombocytopenia. 38
31090599 2019
10
Evidence of complement activation in the thrombotic small vessels of a patient with catastrophic antiphospholipid syndrome treated with eculizumab. 38
30844561 2019
11
A Case of Probable Catastrophic Antiphospholipid Syndrome Treated With Rituximab and Without Anticoagulation. 38
31124923 2019
12
Rare case of catastrophic antiphospholipid syndrome with spontaneous intracranial haemorrhage. 38
30898956 2019
13
Catastrophic Antiphospholipid Syndrome as a Cause of Severe Gastrointestinal Bleeding. 38
30904512 2019
14
Strategies for eliciting and synthesizing evidence for guidelines in rare diseases. 38
30922227 2019
15
High risk of adverse pregnancy outcomes in women with a persistent lupus anticoagulant. 38
30837214 2019
16
Catastrophic Antiphospholipid Syndrome Presenting as Congestive Heart Failure in a Patient with Thrombotic Microangiopathy. 38
30833839 2019
17
Tumid lupus erythematosus-like pseudovasculitic lesions in catastrophic antiphospholipid syndrome. 38
30733989 2019
18
A probable case of catastrophic antiphospholipid syndrome: Should high-dose steroids be given in the setting of polymicrobial sepsis? 38
30967955 2019
19
Catastrophic antiphospholipid syndrome causing ST-segment elevation myocardial infarction with non-obstructive coronary arteries. 38
30635301 2019
20
Therapeutic Plasma Exchange Outcomes in Cairo University Hospitals: 6 Years Experience. 38
30009495 2018
21
[Case series and clinical analysis of 14 cases of catastrophic antiphospholipid syndrome]. 38
30562777 2018
22
Therapeutic response to glucocorticoids, anticoagulation and plasma exchange in a patient with primary antiphospholipid syndrome presenting with purpura fulminans. 38
30290709 2018
23
Bilateral central retinal artery occlusion from catastrophic antiphospholipid syndrome. 38
30420561 2018
24
Eculizumab for catastrophic antiphospholipid syndrome-a case report and literature review. 38
30101319 2018
25
Post-partum catastrophic antiphospholipid syndrome presenting with shock and digital ischaemia - A diagnostic and management challenge. 38
30515245 2018
26
Eculizumab in a pregnant patient with laboratory onset of catastrophic antiphospholipid syndrome: A case report. 38
30290624 2018
27
Co-existing Bilateral Pulmonary Embolism and Intra-cardiac Mass: A Case of Catastrophic Antiphospholipid Syndrome-like Disease. 38
30546985 2018
28
Acute syndrome of pan-epidermolysis and thrombotic storm arising in a patient with systemic lupus erythematosus. 38
30306116 2018
29
Catastrophic antiphospholipid syndrome: Lessons from 14 cases successfully treated in a single center. A narrative report. 38
30146007 2018
30
Total penile necrosis as a manifestation of catastrophic antiphospholipid syndrome. 38
31268004 2018
31
[A child of thrombotic storm controlled by rivaroxaban]. 38
30078248 2018
32
The diagnosis and clinical management of the catastrophic antiphospholipid syndrome: A comprehensive review. 38
29779928 2018
33
Microthrombotic renal involvement in an SLE patient with concomitant catastrophic antiphospholipid syndrome: the beneficial effect of rituximab treatment. 38
29635999 2018
34
Monophasic Disease Course in Systemic Lupus Erythematosus. 38
29858240 2018
35
The complex treatment including rituximab in the Management of Catastrophic Antiphospholid Syndrome with renal involvement. 38
29884138 2018
36
McMaster RARE-Bestpractices clinical practice guideline on diagnosis and management of the catastrophic antiphospholipid syndrome. 38
29978552 2018
37
Catastrophic antiphospholipid syndrome (Ronald Asherson syndrome) and obstetric pathology. 38
28829758 2018
38
["Seronegative" catastrophic antiphospholipid syndrome in pediatrics: Clinical case]. 38
29799892 2018
39
Catastrophic antiphospholipid syndrome and pregnancy. 38
29179957 2018
40
Therapeutic apheresis in the treatment of catastrophic antiphospholipid syndrome. 38
29478799 2018
41
Probable Catastrophic Antiphospholipid Syndrome with Intracerebral Hemorrhage Secondary to Epstein-Barr Viral Infection. 38
28357636 2018
42
Catastrophic antiphospholipid syndrome (CAPS)-induced ischemic pancreatic ducts injury mimicking intraductal papillary mucinous neoplasm (IPMN). 38
28802775 2018
43
Rare Presentation of Catastrophic Antiphospholipid Syndrome with Myocarditis in Post-partum Period: Case Report and Review of Literature. 38
29391679 2018
44
The role of hydroxychloroquine in catastrophic antiphospholipid syndrome case: Series of two case reports and review of literature. 38
30046446 2018
45
Immunomodulation in the Treatment of Refractory Catastrophic Antiphospholipid Syndrome. 38
29805821 2018
46
Clinical Report of Probable Catastrophic Antiphospholipid Syndrome in Pregnancy. 38
29808136 2018
47
Variants in chondroitin sulfate metabolism genes in thrombotic storm. 38
29178990 2018
48
The Wolf Hidden behind the Clots: Catastrophic Antiphospholipid Antibody Syndrome. 38
30123280 2018
49
Catastrophic antiphospholipid antibody syndrome presenting as acute vascular occlusion in a young female patient. 38
27745843 2018
50
Lethal End of Spectrum of Clots-Thrombotic Storm. 38
29977623 2018

Variations for Catastrophic Antiphospholipid Syndrome

Expression for Catastrophic Antiphospholipid Syndrome

Search GEO for disease gene expression data for Catastrophic Antiphospholipid Syndrome.

Pathways for Catastrophic Antiphospholipid Syndrome

GO Terms for Catastrophic Antiphospholipid Syndrome

Cellular components related to Catastrophic Antiphospholipid Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.56 SERPINE1 PROC F5 F3 CFH CD40LG
2 cell surface GO:0009986 9.46 F3 CD40LG APOH ADAMTS13
3 collagen-containing extracellular matrix GO:0062023 9.43 SERPINE1 F3 APOH
4 extracellular space GO:0005615 9.23 SERPINE1 PROC F5 F3 CFH CD40LG

Biological processes related to Catastrophic Antiphospholipid Syndrome according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 platelet degranulation GO:0002576 9.54 SERPINE1 F5 APOH
2 blood coagulation GO:0007596 9.46 PROC F5 F3 ADAMTS13
3 blood circulation GO:0008015 9.4 MTHFR F5
4 positive regulation of blood coagulation GO:0030194 9.32 SERPINE1 APOH
5 negative regulation of fibrinolysis GO:0051918 9.26 SERPINE1 APOH
6 negative regulation of blood coagulation GO:0030195 9.13 SERPINE1 PROC APOH
7 hemostasis GO:0007599 8.92 PROC F5 F3 ADAMTS13

Sources for Catastrophic Antiphospholipid Syndrome

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....